A phase I trial of mRNA-1388 for the prevention of chikungunya virus infection

Trial Profile

A phase I trial of mRNA-1388 for the prevention of chikungunya virus infection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs MRNA 1388 (Primary)
  • Indications Chikungunya virus infections
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 14 Sep 2017 According to a Moderna Therapeutics media release, this trial is supported by Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense.
    • 14 Sep 2017 Status changed from planning to recruiting, according to a Moderna Therapeutics media release.
    • 13 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top